Business Description
Viracta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92765F1084
Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.1 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 1.4 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -33.7 | |||||
| 3-Year EPS without NRI Growth Rate | -36.9 | |||||
| 3-Year FCF Growth Rate | -33.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.85 | |||||
| 9-Day RSI | 37.49 | |||||
| 14-Day RSI | 41.47 | |||||
| 6-1 Month Momentum % | 62.9 | |||||
| 12-1 Month Momentum % | -0.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | |||||
| Quick Ratio | 1.43 | |||||
| Cash Ratio | 1.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | -51.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -126.8 | |||||
| ROA % | -66.87 | |||||
| ROIC % | -366.04 | |||||
| ROC (Joel Greenblatt) % | -8161.84 | |||||
| ROCE % | -87.67 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.31 | |||||
| Price-to-Tangible-Book | 2.32 | |||||
| EV-to-EBIT | -0.15 | |||||
| EV-to-EBITDA | -0.15 | |||||
| EV-to-FCF | -0.18 | |||||
| Price-to-Net-Current-Asset-Value | 2.67 | |||||
| Price-to-Net-Cash | 1.95 | |||||
| Earnings Yield (Greenblatt) % | -666.67 | |||||
| FCF Yield % | -133.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viracta Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.224 | ||
| Beta | 0.11 | ||
| Volatility % | 98.09 | ||
| 14-Day RSI | 41.47 | ||
| 14-Day ATR (€) | 0.041728 | ||
| 20-Day SMA (€) | 0.78225 | ||
| 12-1 Month Momentum % | -0.98 | ||
| 52-Week Range (€) | 0.396 - 2 | ||
| Shares Outstanding (Mil) | 39.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viracta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viracta Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Viracta Therapeutics Inc Frequently Asked Questions
What is Viracta Therapeutics Inc(STU:RYIS)'s stock price today?
The current price of STU:RYIS is €0.72. The 52 week high of STU:RYIS is €2.00 and 52 week low is €0.40.
When is next earnings date of Viracta Therapeutics Inc(STU:RYIS)?
The next earnings date of Viracta Therapeutics Inc(STU:RYIS) is 2024-08-14 Est..
Does Viracta Therapeutics Inc(STU:RYIS) pay dividends? If so, how much?
Viracta Therapeutics Inc(STU:RYIS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers